Biotech Completes Dose Escalation Part of Phase 1 Study of COTI-2 in Gynecological Cancers

Biotech Completes Dose Escalation Part of Phase 1 Study of COTI-2 in Gynecological Cancers
The dose escalation part of a Phase 1 trial evaluating COTI-2 in women with advanced gynecological cancers who did not respond to standard therapy has been completed, according to the drug’s manufacturer, Critical Outcome Technologies Inc. (COTI). The COTI2-101 Phase 1 study (NCT02433626) will now progress to include patients with head and neck squamous cell carcinoma (HNSCC) and

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *